Dyne Therapeutics Expands Hercules Capital Debt Facility to Up to $400 Million

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on developing therapies for genetically driven neuromuscular diseases, announced it has... Read More

The post Dyne Therapeutics Expands Hercules Capital Debt Facility to Up to $400 Million appeared first on citybiz.